sellWeak cluster of 210b5-1 plan
Scott Akamine sold $676k of CERE
Chief Legal Officer at Cerevel Therapeutics Holdings, Inc.. 17,500 shares at an average of $38.64, traded Dec 5, 2023, filed Dec 7, 2023.
Warning score
28Value
$676k
17,500 shares
Holdings after
513
-218% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +20Trade size$676k at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-23-068887, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 5, 2023 | MOption exercise Common Stock10b5-1 | +7,500 | $13.17 | $99k | 8,013 | Dec 7, 2023 |
| Dec 5, 2023 | SOpen-market sale Common Stock10b5-1 | -7,500 | $35.00 | $263k | 513 | Dec 7, 2023 |
| Dec 7, 2023 | MOption exercise Common Stock10b5-1 | +10,000 | $13.17 | $132k | 10,513 | Dec 7, 2023 |
| Dec 7, 2023 | SOpen-market sale Common Stock10b5-1 | -10,000 | $41.37 | $414k | 513 | Dec 7, 2023 |
| Dec 5, 2023 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 264,262 | Dec 7, 2023 |
| Dec 7, 2023 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 254,262 | Dec 7, 2023 |
Related signals
Other insiders at Cerevel Therapeutics Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.0M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 23Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $104k 2,506 shares | -14% | |
| 27Weak | Cerevel Therapeutics Holdings, Inc. | John Renger Chief Scientific Officer | $90k 2,161 shares | -25% | |
| 40Moderate | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -95% | |
| 21Weak | Cerevel Therapeutics Holdings, Inc. | Ramiro Sanchez Chief Medical Officer | $425k 10,000 shares | -41% | |
| 35Weak | Cerevel Therapeutics Holdings, Inc. | Kenneth DiPietro Chief Human Resources Officer | $332k 8,000 shares | -24% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.